Cargando…

Chronic activation of PPARα with fenofibrate reduces autophagic proteins in the liver of mice independent of FGF21

Autophagy is a catabolic mechanism to degrade cellular components to maintain cellular energy levels during starvation, a condition where PPARα may be activated. Here we report a reduced autophagic capacity in the liver following chronic activation of PPARα with fenofibrate (FB) in mice. Chronic adm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Eunjung, Li, Songpei, Liang, Qingning, Zhang, Xinmei, Wang, Hao, Herbert, Terence P., Jenkins, Trisha A., Xu, Aimin, Ye, Ji-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396863/ https://www.ncbi.nlm.nih.gov/pubmed/28422956 http://dx.doi.org/10.1371/journal.pone.0173676

Ejemplares similares

Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension
por: Li, Chuan-Bao, et al.
Publicado: (2009)

Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro
por: Majeed, Yasser, et al.
Publicado: (2019)

The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia
por: Rolland, Benjamin, et al.
Publicado: (2012)

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
por: de la Rosa Rodriguez, Montserrat A., et al.
Publicado: (2018)

Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis
por: Qiu, Han, et al.
Publicado: (2022)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance
por: Liu, Jia, et al.
Publicado: (2016)

HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
por: Jia, Zhankui, et al.
Publicado: (2014)

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2016)

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism()()
por: Huang, Jianfeng, et al.
Publicado: (2013)

Fenofibrate suppresses corneal neovascularization by regulating lipid metabolism through PPARα signaling pathway
por: Zhou, Tong, et al.
Publicado: (2022)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
por: Kitamura, Shigeki, et al.
Publicado: (2023)

Autotaxin, PPARs, and FGF21: An Eye Opener for Progressive Liver Disease?
por: Beuers, Ulrich, et al.
Publicado: (2022)

A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response
por: Iroz, Alison, et al.
Publicado: (2017)

Fatty Acid Desaturase 1 Influences Hepatic Lipid Homeostasis by Modulating the PPARα‐FGF21 Axis
por: Athinarayanan, Shaminie, et al.
Publicado: (2020)

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2015)

Fenofibrate Ameliorates Hepatic Ischemia/Reperfusion Injury in Mice: Involvements of Apoptosis, Autophagy, and PPAR-α Activation
por: Zhang, Jie, et al.
Publicado: (2021)

PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
por: Liu, Tiantian, et al.
Publicado: (2023)

PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study
por: Feng, Xiaomeng, et al.
Publicado: (2017)

Fenofibrate Decreases Ethanol-Induced Neuroinflammation and Oxidative Stress and Reduces Alcohol Relapse in Rats by a PPAR-α-Dependent Mechanism
por: Ibáñez, Cristina, et al.
Publicado: (2023)

PPAR-α Agonist Fenofibrate Suppressed the Formation of Ocular Surface Squamous Metaplasia Induced by Topical Benzalkonium Chloride
por: He, Huan, et al.
Publicado: (2020)

Activation of PPARα by Fenofibrate Attenuates the Effect of Local Heart High Dose Irradiation on the Mouse Cardiac Proteome
por: Azimzadeh, Omid, et al.
Publicado: (2021)

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
por: Honda, Akihiro, et al.
Publicado: (2022)

Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice
por: Murru, Elisabetta, et al.
Publicado: (2022)

Role of PPARα in the Control of Torpor through FGF21-NPY Pathway: From Circadian Clock to Seasonal Change in Mammals
por: Ishida, Norio
Publicado: (2009)

SMP30-mediated synthesis of vitamin C activates the liver PPARα/FGF21 axis to regulate thermogenesis in mice
por: Lee, Bonggi, et al.
Publicado: (2022)

ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα -mediated inhibition of Glioma cell motility in vitro
por: Drukala, Justyna, et al.
Publicado: (2010)

The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia
por: De Felice, Marta, et al.
Publicado: (2018)

Fenofibrate promotes PPARα-targeted recovery of the intestinal epithelial barrier at the host-microbe interface in dogs with diabetes mellitus
por: Crakes, Katti R., et al.
Publicado: (2021)

Erratum. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans. Diabetes 2008;57:1246–1253
por: Zhang, Xinmei, et al.
Publicado: (2019)

PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
por: Silswal, Neerupma, et al.
Publicado: (2012)

(+)-Dehydrovomifoliol Alleviates Oleic Acid-Induced Lipid Accumulation in HepG2 Cells via the PPARα–FGF21 Pathway
por: Xi, Yiyuan, et al.
Publicado: (2021)

CREBH Improves Diet-Induced Obesity, Insulin Resistance, and Metabolic Disturbances by FGF21-Dependent and FGF21-Independent Mechanisms
por: Satoh, Aoi, et al.
Publicado: (2020)

In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer
por: Saidi, Samir A, et al.
Publicado: (2006)

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
por: Bao, Wen, et al.
Publicado: (2021)

L-carnitine and PPARα-agonist fenofibrate are involved in the regulation of Carnitine Acetyltransferase (CrAT) mRNA levels in murine liver cells
por: Kienesberger, Klemens, et al.
Publicado: (2014)

A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy
por: Zeng, Si-Yu, et al.
Publicado: (2018)

The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity
por: Nikam, Aniket, et al.
Publicado: (2018)

Estradiol-dependent and independent effects of FGF21 in obese female mice
por: Jakovleva, T.V., et al.
Publicado: (2022)

FGF19 subfamily members: FGF19 and FGF21
por: Dolegowska, Katarzyna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eg6a8isceoouc3g8ravi8g7qtn